ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$2.47 USD
+0.18 (7.86%)
Updated Jul 11, 2024 03:52 PM ET
After-Market: $2.46 -0.01 (-0.40%) 7:14 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for ASLAN Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 0 | 0 | 0 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 12 | 0 | 0 | 0 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 56 | 48 | 34 | 16 | 48 |
Income After Depreciation & Amortization | -44 | -48 | -34 | -16 | -46 |
Non-Operating Income | 4 | 0 | 4 | 1 | 0 |
Interest Expense | 4 | 4 | 2 | 1 | 1 |
Pretax Income | -44 | -51 | -32 | -17 | -47 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -51 | -32 | -17 | -47 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -44 | -51 | -31 | -16 | -47 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -48 | -34 | -16 | -45 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -44 | -48 | -34 | -16 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.06 | 1.74 | 1.63 | 0.96 | 0.81 |
Diluted EPS Before Non-Recurring Items | -21.52 | -29.44 | -19.20 | -16.00 | -29.60 |
Diluted Net EPS (GAAP) | -21.52 | -29.44 | -19.20 | -16.00 | -58.00 |
Fiscal Year end for ASLAN Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 12.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 12.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.30 | 12.85 | 10.42 | 14.37 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.30 | -12.85 | -10.42 | -2.37 |
Non-Operating Income | NA | 0.04 | 0.37 | 1.87 | 1.66 |
Interest Expense | NA | 0.67 | 1.00 | 1.13 | 1.13 |
Pretax Income | NA | -9.92 | -13.47 | -9.68 | -1.83 |
Income Taxes | NA | 0.00 | 0.04 | 0.03 | 0.06 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.92 | -13.51 | -9.71 | -1.89 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.92 | -13.51 | -9.71 | -1.89 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.85 | 2.16 | 2.15 | 2.06 |
Diluted EPS Before Non-Recurring Items | NA | -10.32 | -6.24 | -4.48 | -0.88 |
Diluted Net EPS (GAAP) | NA | -4.24 | -5.84 | -4.48 | -0.88 |